Iovance Biotherapeutics, Inc. IOVA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $285.61M+8.4% | $263.5M+5.2% | $250.43M+3.7% | $241.53M+13.6% | $212.68M+29.6% | ||
| $180.75M-0.1% | $180.97M+3.0% | $175.65M+4.1% | $168.69M+17.6% | $143.39M+32.8% | ||
| $104.86M+27.0% | $82.54M+10.4% | $74.78M+2.7% | $72.84M+5.1% | $69.29M+23.4% | ||
| 36.7%+5.4pp | 31.3%+1.5pp | 29.9%-0.3pp | 30.2%-2.4pp | 32.6%-1.6pp | ||
| $288.23M-4.5% | $301.71M+0.1% | $301.51M+2.8% | $293.37M+6.3% | $276.09M-1.4% | ||
| $147.6M-3.2% | $152.45M-3.7% | $158.38M-2.9% | $163.16M-1.1% | $165.03M+8.1% | ||
| —— | —— | —— | —— | —— | ||
| $36.41M+1.3% | $35.94M+1.0% | $35.58M-2.0% | $36.3M+21.2% | $29.95M+20.5% | ||
| $648.79M-2.7% | $666.86M0.0% | $666.9M+2.3% | $652.16M+6.7% | $611.46M+9.3% | ||
| -$363.18M+10.0% | -$403.36M+3.1% | -$416.47M-1.4% | -$410.64M-3.0% | -$398.78M-0.9% | ||
| -127.2%+25.9pp | -153.1%+13.2pp | -166.3%+3.7pp | -170%+17.5pp | -187.5%+53.4pp | ||
| $8.42M-18.3% | $10.31M-43.2% | $18.14M-13.2% | $20.9M+3.7% | $20.16M-0.6% | ||
| -$354.76M+9.7% | -$393.05M+1.3% | -$398.33M-2.2% | -$389.73M-2.9% | -$378.62M-1.0% | ||
| -$1.08M+52.0% | -$2.26M— | —— | —— | —— | ||
| -$353.86M+9.5% | -$390.98M+1.7% | -$397.63M-2.0% | -$389.92M-3.9% | -$375.36M-0.9% | ||
| -123.9%+24.5pp | -148.4%+10.4pp | -158.8%+2.7pp | -161.4%+15.1pp | -176.5%+50.3pp | ||
| —— | —— | —— | -$1.22+0.8% | -$1.23+4.7% | ||
| -$0.92+15.6% | -$1.09+8.4% | -$1.19+2.5% | -$1.22+0.8% | -$1.23+4.7% | ||
| —— | —— | —— | 1.3B+4.1% | 1.2B+5.0% | ||
| 1.5B+6.9% | 1.4B+5.1% | 1.3B+4.9% | 1.3B+4.1% | 1.2B+5.0% | ||
| $5.89M-19.2% | $7.29M-20.5% | $9.17M-15.3% | $10.83M— | —— | ||
| $22.16M-17.8% | $26.96M-22.4% | $34.73M-20.2% | $43.52M— | —— | ||
| $21.89M-19.9% | $27.33M-25.8% | $36.83M-19.0% | $45.49M— | —— | ||
| $285.61M+8.4% | $263.5M+5.2% | $250.43M+3.7% | $241.53M+13.6% | $212.68M+29.6% | ||
| $49.93M-18.9% | $61.58M-23.7% | $80.74M-19.1% | $99.84M-13.5% | $115.36M+5.2% | ||
| —— | $61.58M-16.3% | $73.59M-14.0% | $85.6M-12.3% | $97.61M-11.0% | ||
| -$363.18M+10.0% | -$403.36M+3.1% | -$416.47M-1.4% | -$410.64M-3.0% | -$398.78M-0.9% | ||
| -$350.25M+10.3% | -$390.68M+3.4% | -$404.24M-1.5% | -$398.39M-3.0% | -$386.93M-1.0% | ||
| -$350.25M+10.3% | -$390.68M+3.4% | -$404.24M-1.5% | -$398.39M-3.0% | -$386.93M-1.0% | ||
| -122.6%+25.6pp | -148.3%+13.2pp | -161.4%+3.5pp | -164.9%+17.0pp | -181.9%+51.5pp | ||
| -$363.18M+10.0% | -$403.36M+3.1% | -$416.47M-1.4% | -$410.64M-3.0% | -$398.78M-0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s revenue?
- Iovance Biotherapeutics, Inc. (IOVA) generated $285.6M in revenue over the trailing twelve months, up 34.3% year over year.
- Is Iovance Biotherapeutics, Inc. profitable?
- Iovance Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $353.9M over the trailing twelve months, a -123.9% net margin.
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Gross margin is 36.7% and operating margin is -127.2%, with a -123.9% net margin.
- What is Iovance Biotherapeutics, Inc.'s earnings per share?
- Iovance Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.13.
- Where does Iovance Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
